Difference between revisions of "Sarcomatoid renal cell carcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 75%; text-align:center;"" to "{| class="wikitable" style="width: 60%; text-align:center;"") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
Line 28: | Line 28: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566570/ Haas et al. 2012 (ECOG 8802)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566570/ Haas et al. 2012 (ECOG 8802)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 |
|- | |- | ||
|} | |} | ||
Line 57: | Line 57: | ||
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.29503/abstract Michaelson et al. 2015 (MGH 07-212)] | |[https://onlinelibrary.wiley.com/doi/10.1002/cncr.29503/abstract Michaelson et al. 2015 (MGH 07-212)] | ||
|2007-2013 | |2007-2013 | ||
− | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 |
|- | |- | ||
|} | |} |
Revision as of 18:02, 12 February 2022
Section editor | |
---|---|
Ali Raza Khaki, MD Stanford University Palo Alto, CA ![]() |
Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.
2 regimens on this page
2 variants on this page
|
Metastatic disease, first-line
Doxorubicin & Gemcitabine
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Haas et al. 2012 (ECOG 8802) | 2004-2007 | Phase 2 |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg/m2 IV push once on day 1
- Gemcitabine (Gemzar) 1500 mg/m2 IV over 30 minutes once on day 1
Supportive medications
- One of the following:
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)
References
- ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article contains verified protocol link to PMC article PubMed NCT00068393
Gemcitabine & Sunitinib
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Michaelson et al. 2015 (MGH 07-212) | 2007-2013 | Phase 2 |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
Targeted therapy
- Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 14
21-day cycles
References
- MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article PubMed NCT00556049